Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxCommon IBS/IBD Treatment Blunts COVID-19 Vaccine Response

The research, taken from the CLARITY study and published in GUT, found that 865 people given the Pfizer/BioNTech or the Oxford/AZ COVID-19 vaccine and treated with infliximab (Remicade) had significantly lower concentrations of antibodies when compared to 428 people on an alternative treatment, vedolizumab (Entyvio). Infliximab is prescribed to around two million people worldwide.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form